Novartis Q4 Results

Content Click below to navigate through the document ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor ↓ ↑ Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic Immunology Neuroscience > Oncology Other Global Health Abbreviations References NCT05653349 VAYHIT1 (CVAY736112301) Indication Phase Patients Primary Outcome Measures Arms Intervention 1L Immune Thrombocytopenia Phase 3 225 Time from randomization to treatment failure (TTF) NCT05653219 VAYHIT2 (CVAY736Q12301) Indication Phase 2L Immune Thrombocytopenia Phase 3 Time from randomization to treatment failure (TTF) Patients 150 Primary Outcome Measures Arms Intervention Arm 1: Experimental: lanalumab Lower dose administered intravenously with corticosteroids oral or parentally (if clinically justified) Arm 2: lanalumab Higher dose administered intravenously with corticosteroids oral or parentally (if clinically justified) Arm 3: Placebo Comparator administered intravenously with corticosteroids oral or parentally (if clinically justified) Target Patients Readout Milestone(s) Adult patients with primary ITP 2025 Publication TBD Target Patients Readout Milestone(s) Publication Arm 1: Experimental: eltrombopag and ianalumab lower dose Arm 2: Experimental: eltrombopag and ianalumab higher dose Arm 3: eltrombopag and placebo Primary ITP patients who failed steroids. 2025 TBD □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 70

View entire presentation